Hostname: page-component-89b8bd64d-4ws75 Total loading time: 0 Render date: 2026-05-06T11:51:48.692Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of botulinum toxin type A injection for intrinsic rhinitis

Published online by Cambridge University Press:  29 June 2007

Kyung-Su Kim ,
Sung-Shik Kim ,
Joo-Heon Yoon  and
Jae Wook Han
Kyung-Su Kim*
Affiliation:
Department of Otorhinolaryngology, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Sung-Shik Kim
Affiliation:
Department of Otorhinolaryngology, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Joo-Heon Yoon
Affiliation:
Department of Otorhinolaryngology, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Jae Wook Han
Affiliation:
Department of Otorhinolaryngology, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
*
Address for correspondence: Kyung-Su Kim, M.D., Department of Otorhinolaryngology, Yongdong Severance Hospital, Yonsei University College of Medicine, Yongdong P.O. Box 1217, Seoul, Korea. Fax: 82-2-3463-4750 e-mail: ydent@yumc.yonsei.ackr
Get access Rights & Permissions [Opens in a new window]

Abstract

Botulinum toxin type A (BTA) is known to inhibit the release of acetylcholine from cholinergic nerve endings. Owing to the characteristics of BTA, we thought that it could be used for the treatment of intrinsic rhinitis acting as an anticholinergic drug. In a double-blind placebo-controlled study four units of BTA were injected into the middle turbinate (two units) and inferior turbinate (two units) in each nasal cavity. Rhinorrhoea, nasal obstruction, and sneezing were recorded in a symptom diary on the basis of a scale of 5 and the number of paper tissues used per day was also recorded for 24 weeks. Rhinorrhoea was significantly diminished in severity (24.1–41.5 per cent reduction) and paper tissue use (54.3 per cent reduction) in the BTA group compared with the placebo group. This effect could be maintained for four weeks. Sneezing and nasal stuffiness were not affected by BTA. These results suggest that BTA can be used to treat rhinorrhoea in intrinsic rhinitis patients, however, the effective period is short.

Keywords

Botulinum toxinsRhinitis, intrinsic

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 112 , Issue 3 , March 1998 , pp. 248 - 251
Copyright
Copyright © JLO (1984) Limited 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Adams, S. G., Durkin, L. C., Irish, J. C., Hunt, E. J. (1996) Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia. Laryngoscope 106: 296–300.CrossRefGoogle ScholarPubMed
Anggard, A. (1974) The effects of parasympathetic nerve stimulation on the microcirculation and secretion in the nasal mucosa of the cat. Ada Otolaryngologica 78: 98–105.Google Scholar
Black, J. D., Dolly, J. O. (1986) Interaction of 125I-labelled botulinum neurotoxins with nerve terminals: I. ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for type A and B on motor nerves. Journal of Cell Biology 103: 521–534.Google Scholar
Bushara, K. O., Park, D. M. (1994) Botulinum toxin and sweating. Journal of Neurology, Neurosurgery and Psychiatry 57: 1437–1438.Google Scholar
Carruthers, A., Kiene, K., Carruthers, J. (1996) Botulinum A exotoxin use in clinical dermatology. Journal of the American Academy of Dermatology 34(5): 788–797.Google Scholar
Cauna, N. (1982) Blood and nerve supply of the nasal lining. In The Nose. Upper Airway Physiology and the Atmospheric Environment. (Procor, D. F., Andersen, I., eds.), Elsevier Biomedical Press, Amsterdam, pp 45–69.Google Scholar
Dolovich, J., Kenedy, L., Vickerson, F., Kazim, F. (1987) Control of the hypersection of vasomotor rhinitis by topical ipratropium bromide. Journal of Allergy and Clinical Immunology 80: 274–278.Google Scholar
Doyle, W. J., Riker, D. K., McBride, T. P., Hayden, F. G., Hendley, J. O., Swarts, J. D., Gwaltney, J. M. (1993) Therapeutic effects of an anticholinergic-symptomatic combination in induced rhinovirus colds. Annals of Otology, Rhinology and Laryngology 102: 521–527.Google Scholar
Jankovic, J., Brin, M. F. (1991) Therapeutic uses of botulinum toxin. New England Journal of Medicine 324: 1186–1194.Google Scholar
Kimmelman, C. P., Ali, G. H. A. (1986) Vasomotor rhinitis. Otolaryngologic Clinics of North America 19: 65–71.Google Scholar
Koriwchak, M. J., Netterville, J. L., Snowden, T., Courey, M., Ossoff, R. H. (1996) Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope 106: 1476–1481.Google Scholar
Lee, M. C. (1992) Spasmodic torticollis: Medical and botulinum A toxin treatment. Yonsei Medical Journal 33(4): 289–293.Google Scholar
Middlebrook, J. L. (1989) Cell surface receptors for protein toxins. In Botulinum Neurotoxin and Tetanus Neurotoxin. (Simpson, L. L., ed.), Academic Press, San Diego, California, pp 95–119.Google Scholar
Mygind, N., Borum, P. (1983) Effect of cholino-ceptor antagonist in the nose. European Journal of Respiratory Disease 64(Suppl 128): 167–174.Google Scholar
Mygind, N., Borum, P. (1989) Intranasal ipratropium: literature abstracts and comments. Rhinology (Suppl 9): 37–4.Google Scholar
Ostberg, B., Birgit, W., Mygind, N. (1987) Cold air-induced rhinorrhoea and high-dose ipratropium. Archives of Otolaryngology-Head and Neck Surgery 113: 160–162.Google Scholar
Principato, J. J. (1979) Chronic vasomotor rhinitis: cryogenic and other surgical modes of treatment. Laryngoscope 89: 619–638.Google Scholar
Schantz, E. J., Johnson, E. A. (1992) Properties and uses of botulinum toxin and other microbial neurotoxins in medicine. Microbiological Review 56: 80–99.Google Scholar
Schulze-Bonhage, A., Schroder, M., Ferbert, A. (1996) Botulinum toxin in the therapy of gustatory sweating. Journal of Neurology 243(2): 143–146.Google Scholar
Scott, A. B., Magoon, E. H., McNeer, K. W., Stager, D. R. (1990) Botulinum treatment of strabismus in children. Transactions of the American Ophthalmological Society Annual Meeting 87: 174–180.Google Scholar
Scott, A. B., Suzuki, D. (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Movement Disorders 3: 333–335.Google Scholar
Shaari, C. M., Sanders, I., Wu, B. -L., Biller, H. F. (1995) Rhinorrhoea is decreased in dogs after nasal application of botulinum toxin. Otolaryngology-Head and Neck Surgery 112(4): 566–571.Google Scholar
Simpson, L. L. (1984) The binding fragment from tetanus toxin antagonizes the neuromuscular blocking actions of botulinum toxin. Journal of Pharmacology and Experimental Therapeutics 229: 182–187.Google Scholar